GOSSAMER BIO INC
GOSSNASDAQ🏆 #3081 by market capEarnings Aug 11 · PreUS Equity
$364.28▼ $21.86 (−6.00%)
Simulated price1h—
24h▼ 6.0%
7d—
14d—
30d—
1y—
🏦Market Cap
$86M
Small Cap
📈Revenue Growth (YoY)
-55.4%
Declining
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
1.6x
Cheap
Otter Score
43
Weak
No chart data available for GOSS.
Trading Snapshot
- Day Range
- $362.95 – $370.65
- 52-Week Range
- $0.11 – $3.87
- Volume
- $1.64B
- Avg Volume
- $1.88B
- Shares Outstanding
- 488.9M
- Next Earnings
- Sep 26, 2026
Fundamentals Snapshot
- Annual Revenue
- $55M
- Last Q Revenue
- $13M
- P/E Ratio
- —
- P/S Ratio
- 1.6x
- EPS (TTM)
- $-0.78
- Dividend Yield
- —
Why Investors Own GOSS
- ✓High-growth profile — revenue up +36.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 63% gross margin and 8% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$55M▲ +35.1% YoY
Gross Margin (TTM)
63.4%▲ +4.2% YoY
Operating Income (TTM)
$7M▲ +35.1% YoY
Free Cash Flow (TTM)
$4M▲ +35.1% YoY
About GOSSAMER BIO INC
A company profile for GOSSAMER BIO INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
43/100
Analyst Price Target
ⓘAverage Target
$452.30
▲ +24.2% Upside
High Target$497.47
Low Target$373.01
Based on 33 analysts
Latest News & Updates
🚀
MarketWatch·2h ago
GOSSAMER BIO INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Reuters·5h ago
Analysts lift GOSS price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Bloomberg·1d ago
GOSSAMER BIO INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.